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Critical events in HIV disease occur in lymphoid tissues
that are often coinfected with other pathogens, in particu-
lar with herpesviruses, which may affect HIV. Here, we
investigated infection by and evolution of R5 and X4 HIV-
1 variants in human lymphoid tissues coinfected ex vivo
with human herpesviruses (HHV) including HHV-6,
HHV-7 and HCMV. We found that both HHV-6 and HHV-
7 selectively suppress R5 replication, favoring X4 emer-
gence as the dominant phenotype, and investigated the
mechanisms of these phenomena. The selective pressure
of HHV-7 on HIV-1 is mediated by down-modulation of
CD4 in coinfected tissues, whereas HHV-6 mediates its
effect on HIV-1 by dramatic upregulation of RANTES. In
macaques coinfected with HHV-6 and SIV, HHV-6-resist-
ant escape mutants are selected. These mutants are resist-
ant to RANTES, or even dependent on this chemokine.
HIV-1 infection does not affect the replication of HHV-6
but significantly changes the replication of CMV and
HHV-7 depending on HIV-1 phenotype.
Thus, human herpesviruses interact with HIV-1 in coin-
fected human lymphoid tissue via mechanisms that
include modulation of HIV receptors and coreceptors,
changing the cytokine/chemokine network, and compet-
ing for the same cell targets. Interactions between herpes-
viruses and HIV might affect the course of HIV disease by
selecting for HIV-1 of a particular phenotype as well as for
escape mutants. These findings support our hypothesis
that interaction of HIV with other microbes in coinfected
tissues can determine the pattern of HIV infection. Deci-
pherment of the mechanisms of this phenomenon may
significantly contribute to the development of efficient
anti-HIV therapies.
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